Refining Cancer Management Using Integrated Liquid Biopsy

Theranostics. 2020 Jan 16;10(5):2374-2384. doi: 10.7150/thno.40677. eCollection 2020.

Abstract

Liquid biopsy has emerged in the last ten years as an appealing noninvasive strategy to support early cancer diagnosis and follow-up interventions. However, conventional liquid biopsy strategies involving specified biomarkers have encountered unexpected inconsistencies stemming from the use of different analytical methodologies. Recent reports have repeatedly demonstrated that integrated detection of multiple liquid biopsy biomarkers can significantly improve diagnostic performance by eliminating the influence of intratumoral heterogeneity. Herein, we review the progress in the field of liquid biopsy and propose a novel integrated liquid biopsy framework consisting of three categories: elementary, intermediate, and advanced integration. We also summarize the merits of the integration strategy and propose a roadmap toward refining cancer diagnosis, metastasis surveillance, and prognostication.

Keywords: Cancer management; Circulating tumor DNA; Circulating tumor cell; Combined detection; Extracellular vesicle..

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Circulating Tumor DNA / genetics
  • Circulating Tumor DNA / metabolism
  • Early Detection of Cancer / methods
  • Extracellular Vesicles / genetics
  • Extracellular Vesicles / metabolism
  • Humans
  • Liquid Biopsy / methods*
  • Neoplasms / diagnosis*
  • Neoplasms / therapy
  • Neoplastic Cells, Circulating / metabolism

Substances

  • Biomarkers, Tumor
  • Circulating Tumor DNA